#eli-lilly

#eli-lilly

Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli Lilly's stock surged more than 50% year-to-date in 2024.

"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, emphasizing the importance of medication access.

Eli Lilly is suing four telehealth companies for selling illegal copies of its weight-loss drug Zepbound, which is based on the active ingredient tirzepatide.

From late 2020 to the summer of 2024, Eli Lilly & Co. stock surged over 635%, driven by innovative medicines and regulatory successes, despite recent revenue shortfalls.

"The drug also lowered patients' blood sugar levels by 1.3% on average, while the overall efficacy of orforglipron in promoting weight loss and controlling diabetes has been met with enthusiasm."

That's where being a savvy investor comes in. Being contrarian, you can pick up these hidden gems at a significant discount and profit all the way to the bank when their fortunes turn.